Clinical trials: Regorafenib
Ovarian Cancer, Primary Peritoneal Cancer
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02278783
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Colorectal Cancer, Liver Metastasis
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy
- Trial name
- NCT05524155
- Testing
- HAIC, Sintilimab, Regorafenib
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Sarcoma
Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
This is an international (France, Austria and Germany), randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of regorafenib in patients with histologically proven metastatic and/or…
- Trial name
- REGO-SARC (NCT01900743)
- Testing
- Regorafenib
- Where
- 25 sites in Austria, France
- Volunteers
- 219 people
- Sponsor
- Centre Oscar Lambret
Metastatic Colorectal Adenocarcinoma
Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer
Managements for refractory proficient mismatch repair (pMMR) or microsatellite stable (MSS) metastatic colorectal cancer (mCRC) were still challenging and controversial.
- Trial name
- NCT05942768
- Testing
- regorafenib plus anti-PD-1 antibodies
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines
Regorafenib has been proved to improved survival in patients with metastatic colorectal cancer who have been failed to all of known standard chemotherapy (The CORRECT study).
- Trial name
- NCT01786538
- Testing
- Regorafenib/FOLFOX
- Where
- South Korea
- Sponsor
- Asan Medical Center
Neoplasms
Effect of Rifampin on the Pharmacokinetics of BAY73-4506
The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.
- Trial name
- NCT01322438
- Testing
- Regorafenib (BAY73-4506) + rifampin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Neoplasms
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Open label Phase I study of Regorafenib to evaluate cardiovascular safety, tolerability and anti-tumor activity in patients with advanced solid tumors
- Trial name
- NCT01339104
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bayer
Rectal Cancer, Rectal Cancer Recurrent
A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer
This is a prospective single-center, single-arm, open-label, phase II study evaluating the safety, activity, and efficacy of regorafenib in combination with lorigerlimab for the treatment of patients with regrowing or locally…
- Trial name
- NCT07223567
- Testing
- Regorafenib, Lorigerlimab
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy
- Trial name
- NCT07722494
- Testing
- IBI363 + bevacizumab, Investigator's choice of therapy
- Where
- 2 sites in China
- Volunteers
- 550 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Colorectal Cancer
A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer
This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intravenous administration of T3011 at different doses in combination with oral regorafenib in the treatment of…
- Trial name
- NCT06200363
- Testing
- T3011, Regorafenib
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
This phase I trial studies the side effects and best dose of regorafenib when given together with ipilimumab and nivolumab in treating patients with microsatellite stable colorectal cancer that has spread to other places in the…
- Conditions
- Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma
- Trial name
- NCT04362839
- Testing
- Ipilimumab, Nivolumab, Regorafenib
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- City of Hope Medical Center
Neoplasms
BAY73-4506 Probe Substrate Study
To evaluate the effect of BAY73-4506 on the pharmacokinetics of probe substrates of CYP 2C9 (warfarin), 2C19 (omeprazole) and 3A4 (midazolam) administered in a cocktail approach and on the pharmacokinetics of a probe substrate of…
- Trial name
- NCT01287598
- Testing
- Regorafenib (Stivarga, BAY73-4506), Warfarin, Omeprazole
- Where
- 4 sites in Canada
- Volunteers
- 41 people
- Sponsor
- Bayer
Metastatic Colorectal Cancer
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
- Trial name
- REPROGRAM-02 (NCT05462613)
- Testing
- quality of life questionnaires, Blood sample, Regorafenib
- Where
- 16 sites in France
- Volunteers
- 446 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Upper GI Cancer
Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers
Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach
- Trial name
- NCT02241720
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Utah
Metastatic Colorectal Cancer (mCRC)
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
Patients with metastatic colorectal cancer (mCRC) who have received all approved standard treatments (except Regorafenib and Lonsurf) no longer have treatment options available while maintaining a good performance status which…
- Trial name
- NEXT-REGIRI (NCT03829462)
- Testing
- Regorafenib, Irinotecan
- Where
- 11 sites in France
- Volunteers
- 377 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Colo-rectal Cancer, Metastatic Cancer
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
The investigators propose a phase II clinical trial with the objective to investigate the potential clinical interest to associate regorafenib with a metronomic chemotherapy combining capecitabine, cyclophosphamide and low-dose…
- Trial name
- REPROGRAM-01 (NCT04534218)
- Testing
- Regorafenib, Cyclophosphamide, Capecitabine
- Where
- 3 sites in France
- Volunteers
- 49 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Solid Tumor
Study of Regorafenib and Sildenafil for Advanced Solid Tumors
This is a phase 1 study of sildenafil in combination with regorafenib in patients with progressive advanced solid tumors. A modified 3+3 dose escalation design will be conducted for the dose escalation of the treatment…
- Trial name
- NCT02466802
- Testing
- Regorafenib, Sildenafil Citrate
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Virginia Commonwealth University
HER2-positive Colorectal Cancer
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and…
- Trial name
- NCT07384377
- Testing
- JSKN003, Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib.
- Volunteers
- 123 people
- Sponsor
- Shanghai JMT-Bio Inc.
Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
This phase II trial studies circulating cell-free tumor DNA testing to guide treatment with regorafenib or TAS-102 in patients with colorectal cancer that has spread to other areas of the body.
- Conditions
- Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8
- Trial name
- NCT03844620
- Testing
- Best Practice, Laboratory Procedure, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Neoplasms
Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic…
- Trial name
- COLONG (NCT03386825)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- Bayer